Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with multiple myeloma (a type of blood cancer)
- People who are considered suitable for a stem cell transplant and whose disease is currently in first remission (meaning the cancer has responded to initial treatment for the first time)
- People who have had a specific test (called ClonoSeq, or another recognised method) that has detected a measurable level of remaining cancer cells in their body
- People whose medical team is able to share anonymised personal and health follow-up information for research purposes
- People who are currently receiving standard treatment for their condition
- People who are able to give their informed agreement to participate in the trial
Who may not be able to join:
- People who do not meet all of the above criteria listed for joining the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Rayan Kaedbey, Sir Mortimer B. Davis - Jewish General Hospital
Phone: 514-340-8222
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To validate the sensitivity of Telo Genomics assay (measurement tool) to detect MRD (measurement expressed in the number of plasma cells per 100000 cells) and establish the clinical utility of TELO - DMRD for MRD enumeration; To assess the utility of TeloView® technology genomic profiling (measurement tool) to stratify post-transplant MM patients into relapse risk groups (dichotomous measure of high or low) by analyzing the residual MRD plasma cells
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.